Clinical Trials Browser

NIH × copanlisib × Clear all

NCT03502733 2026-03-18

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1 Active not recruiting

Lymphoma, Neoplasm Metastasis

NCT04317105 2026-03-18

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04345913 2026-03-18

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT05490771 2026-03-18

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06400238 2026-03-18

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Phase 2 Active not recruiting

35 enrolled 10 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT06360588 2026-03-17

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)

Phase 2 Active not recruiting

22 enrolled 9 charts

Other solid neoplasm

Malignant Solid Neoplasm

NCT03789240 2026-03-03

Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma

Phase 2 Active not recruiting

33 enrolled 17 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT03842228 2025-10-14

COD

Phase 1 Active not recruiting

39 enrolled 15 charts

Neoplasm Metastasis

NCT03939897 2025-09-24

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

Phase 1 Active not recruiting

24 enrolled 15 charts

Breast Neoplasms

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Phase 2 Completed

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1 Terminated

8 enrolled 17 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05295589 2023-09-26

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Phase 2 Withdrawn

Platinum-Refractory Fallopian Tube Carcinoma

NCT03803761 2023-09-25

A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms

NCT03377101 2018-08-14

Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer

Phase 2 Withdrawn

Estrogen Receptor Positive